News >

Neratinib Offers Hope in Treatment of CNS Metastases in HER2+ Breast Cancer

Angelica Welch
Published: Wednesday, Oct 25, 2017

Rachel A. Freedman, MD

Rachel A. Freedman, MD
About 50% of patients with metastatic HER2-positive breast cancer will eventually develop central nervous system (CNS) metastases at some point in their treatment course.

, lead study author Rachel A. Freedman, MD, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, discussed treating patients with HER2-positive breast cancer who develop CNS metastases, and the promise that neratinib holds in this patient population.

OncLive: Can you provide an overview of this study of neratinib and capecitabine in HER2-positive breast cancer?

Freedman: Patients with HER2-positive breast cancer that is metastatic have a high likelihood of developing CNS metastases. Many women will continue to progress in their CNS after local therapies are administered, such as radiation and surgical therapies. It is a real unmet need for our patients, and many patients end up dying of their CNS disease over time.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication